Policy Notices

• New NIH "FORMS-G" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2022
  (NOT-OD-21-169)
  National Institutes of Health
  Agency for Healthcare Research and Quality
  Food and Drug Administration
  

• Update: Notification of Upcoming Change in Federal-wide Unique Entity Identifier Requirements
  (NOT-OD-21-170)
  National Institutes of Health
  Agency for Healthcare Research and Quality
  Food and Drug Administration
  Substance Abuse and Mental Health Services Administration
  Department of Veteran's Affairs
  

General Notices

• Pre-Application Webinar for RFA-CA-21-050, Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed) and RFA-CA-21-051, Coordinating Center for Canine Cancer Immunotherapy Network (K9CIN; U24 Clinical Trial Not Allowed)
  (NOT-CA-21-103)
  National Cancer Institute
  

• Pre-application Webinar for RFA-CA-21-048 - Research Centers for Cancer Systems Biology (U54 Clinical Trial Not Allowed)
  (NOT-CA-21-104)
  National Cancer Institute
  

• Pre-application Webinar for RFA-CA-21-049 - Division of Cancer Biology Multi-Consortia Coordinating Center (U24 Clinical Trial Not Allowed)
  (NOT-CA-21-105)
  National Cancer Institute
  

• Pre-Application Webinar for the "PDAC Stromal Reprograming Consortium (PSRC)": RFA-CA-21-041 and RFA-CA-21-042
  (NOT-CA-21-106)
  National Cancer Institute
  

• Notice of NICHD Participation in PAR-21-253 "Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed)
  (NOT-HD-21-041)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice of Informational Webinar for Funding Opportunities to Build and Provide Content for a New Educational Resource on the Principles of Rigorous Research
  (NOT-NS-22-006)
  National Institute of Neurological Disorders and Stroke
  

• Extension of COVID Flexibilities for Instruction in the Responsible Conduct of Research
  (NOT-OD-21-152)
  National Institutes of Health
  Agency for Healthcare Research and Quality
  

• Guidance on Flexibilities for Conducting Semiannual Inspections of Animal Facilities
  (NOT-OD-21-164)
  Office of the Director, NIH
  

• Adjusted Timeline for Requiring Two-Factor Authentication to Access eRA Modules Using Login.Gov or InCommon Federated Accounts
  (NOT-OD-21-172)
  National Institutes of Health
  

• Technical Assistance Webinar for: Clinical and Translational Science Award (UM1) (PAR-21-293)
  (NOT-TR-21-031)
  National Center for Advancing Translational Sciences
  

• Critical resource gaps and opportunities to support Next Generation Sequencing (NGS) test development, validation, and data interpretation, including through the use of technologies such as artificial intelligence (AI)/machine learning (ML).
  (NOT-OD-21-162)
  Office of the Director, NIH
  Food and Drug Administration
  

• Request for Information: Critical resource gaps and opportunities to support radiological tool development and clinical data interpretation using artificial intelligence (AI)/machine learning (ML)
  (NOT-OD-21-163)
  Office of the Director, NIH
  Food and Drug Administration
  

Notice of Changes to Funding Opportunities

• Notice of Annual Meeting Addition and Budget Language Change in RFA-AG-22-018 "Leveraging Existing Large Databases and Cohorts to Better Understand the Risks and Benefits of Long-Term Osteoporosis Therapy and Drug Holiday (R01 Clinical Trial Not Allowed)"
  (NOT-AG-21-032)
  National Institute on Aging
  

• Notice of Participation of the National Institute of Allergy and Infectious Diseases (NIAID) in PAR-21-248 Pediatric Immune System Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed)
  (NOT-AI-21-073)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Change to Research Objectives and Eligibility of Foreign Components for PAR-20-313 - Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
  (NOT-CA-21-095)
  National Cancer Institute
  

• Notice of Change to Research Objectives and Eligibility of Foreign Components for PAR-20-314 - Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trial Not Allowed)
  (NOT-CA-21-102)
  National Cancer Institute
  

• Notice to Extend the Expiration Date for PAR-19-368, "Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)"
  (NOT-DA-21-068)
  National Institute on Drug Abuse
  National Cancer Institute
  National Institute on Alcohol Abuse and Alcoholism
  

• Notice to Extend the Expiration Date for PAR-19-162, "Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)"
  (NOT-DA-21-069)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  

• Notice to Extend the Expiration Date for PAR-19-163, "Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)"
  (NOT-DA-21-070)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  

• Notice of Change to include NIDA-Specific Interest Areas in PAR-21-280, "Dyadic interpersonal processes and biopsychosocial outcomes (R01, Basic Experimental Studies with Humans)"
  (NOT-DA-21-071)
  National Institute on Drug Abuse
  

• Notice of Change to include NIDA-Specific Interest Areas in PAR-21-281, "Dyadic interpersonal processes and biopsychosocial outcomes (R01, Clinical Trials Not Allowed)"
  (NOT-DA-21-072)
  National Institute on Drug Abuse
  

• Notice of Change to Add Responsiveness Criteria and Further Clarify Clinical Trials Allowed in PAR-20-316 "Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)"
  (NOT-NS-21-076)
  National Institute of Neurological Disorders and Stroke
  National Eye Institute
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  

• Notice of Change to Add Responsiveness Criteria and Further Clarify Clinical Trials Allowed in PAR-19-040 "Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)"
  (NOT-NS-21-078)
  National Institute of Neurological Disorders and Stroke
  National Eye Institute
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  

• Notice of Correction to Key Dates for PAR-21-265 "NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)".
  (NOT-NS-22-007)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Correction to Key Dates for PAR-21-266 "NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)".
  (NOT-NS-22-008)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Correction to Key Dates for PAR-21-267 "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)".
  (NOT-NS-22-009)
  National Institute of Neurological Disorders and Stroke
  

• Notice to Extend Expiration Date and Add a Receipt Date for PA-18-932: Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)
  (NOT-OD-21-168)
  Office of Disease Prevention
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Reissue of Elucidating the Role of Nutrition in Care and Development of Preterm Infants (R01 Clinical Trial Optional)
  (NOT-HD-21-042)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

Notices of Special Interest

• RESCINDED - Notice of Special Interest (NOSI): Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes
  (NOT-AI-21-067)
  National Institute of Allergy and Infectious Diseases
  National Heart, Lung, and Blood Institute
  

• Notice of Special Interest: Administrative Supplements to Participate in the NCI Early-stage Surgeon Scientist Program (ESSP)
  (NOT-CA-21-100)
  National Cancer Institute
  Office of Research on Women's Health
  

• Notice of Special Interest (NOSI): Precision Imaging of Oral Lesions
  (NOT-DE-21-010)
  National Institute of Dental and Craniofacial Research
  National Cancer Institute
  

• Notice of Special Interest: Advancing Research in Gastrointestinal Dysfunction in People with Neurodevelopmental Disorders
  (NOT-DK-21-024)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

Funding Opportunities

• Implementing and Sustaining Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Equity in Outcomes (R34 Clinical Trial Required )
  (PAR-21-283)
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Effectiveness of Implementing Sustainable Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Mental Health Equity for Traditionally Underserved Populations (R01 Clinical Trial Optional)
  (PAR-21-284)
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R01 Clinical Trial Required)
  (PAR-21-291)
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Pilot Studies to Test the Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R34 Clinical Trial Required)
  (PAR-21-292)
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional)
  (PAR-21-303)
  John E. Fogarty International Center
  National Cancer Institute
  National Eye Institute
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Deafness and Other Communication Disorders
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  Office of Behavioral and Social Sciences Research
  Office of Research on Women's Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Brazil Regional Prospective Observational Research in Tuberculosis (RePORT) (U01 Clinical Trial Not Allowed)
  (PAR-21-304)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): Not Applicable
  
  

• Imaging - Science Track Award for Research Transition (I/START) (R03- Basic Experimental Studies with Humans Required)
  (PAR-21-309)
  National Institute on Drug Abuse
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Imaging - Science Track Award for Research Transition (I/START) (R03- Clinical Trial Optional)
  (PAR-21-310)
  National Institute on Drug Abuse
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Multi-Disciplinary Collaborations to Understand Mechanisms of Systemic Immune Signaling and Inflammation in ADRD and its Progression (R01 Clinical Trial Not Allowed)
  (PAR-22-023)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): October 22, 2021
  
  

• Acquired Resistance to Therapy Network (ARTNet; U54 Clinical Trial Not Allowed)
  (RFA-CA-21-052)
  National Cancer Institute
  Application Receipt Date(s): November 01, 2021
  
  

• Coordinating and Data Management Center for Acquired Resistance to Therapy Network (ARTNet; U24 Clinical Trial Not Allowed)
  (RFA-CA-21-053)
  National Cancer Institute
  Application Receipt Date(s): November 01, 2021
  
  

• Cardiovascular Biorepository for Type 1 Diabetes (U24 Clinical Trial Not Allowed)
  (RFA-DK-21-010)
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): October 20, 2021
  
  

• Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase 1: Data Production Research and Development Centers (UM1 Clinical Trial Not Allowed)
  (RFA-HG-21-029)
  National Human Genome Research Institute
  Application Receipt Date(s): November 1, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase 1: Data Analysis and Validation Centers (U01 Clinical Trial Not Allowed)
  (RFA-HG-21-030)
  National Human Genome Research Institute
  Application Receipt Date(s): November 1, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase 1: Data Resource and Administrative Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-HG-21-031)
  National Human Genome Research Institute
  Application Receipt Date(s): November 1, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Genome Research Experiences to Attract Talented Undergraduates into the Genomics Field to Enhance Diversity (R25 Clinical Trial Not Allowed)
  (RFA-HG-21-033)
  National Human Genome Research Institute
  Application Receipt Date(s): December 1, 2021; July 1, 2022; July 1, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• New Investigators to Promote Workforce Diversity in Genomics, Bioinformatics, or Bioengineering and Biomedical Imaging Research (R01 Clinical Trial Optional)
  (RFA-HG-21-041)
  National Human Genome Research Institute
  National Institute of Biomedical Imaging and Bioengineering
  Office of the Director, NIH
  Application Receipt Date(s): October 20, 2021
  
  

• Biomarkers for the Lewy Body Dementias (U01 Clinical Trial Not Allowed)
  (RFA-NS-22-001)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): October 22, 2021
  
  

• Leveraging Existing Data Resources for Computational Model and Tool Development to Discover Novel Candidate Mechanisms and Biomarkers for ADRD (R01 Clinical Trial Not Allowed)
  (RFA-NS-22-006)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): October 26, 2021